Cellectis (CLLS)
(Delayed Data from NSDQ)
$2.26 USD
-0.06 (-2.72%)
Updated Sep 20, 2024 03:59 PM ET
After-Market: $2.26 0.00 (0.13%) 7:58 PM ET
3-Hold of 5 3
B Value B Growth F Momentum B VGM
Price, Consensus and EPS Surprise
CLLS 2.26 -0.06(-2.72%)
Will CLLS be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for CLLS based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for CLLS
CERVOMED INC (CRVO) Soars 10.6%: Is Further Upside Left in the Stock?
Regenxbio (RGNX) Surges 18.3%: Is This an Indication of Further Gains?
CLLS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Down -22.78% in 4 Weeks, Here's Why You Should You Buy the Dip in Cellectis (CLLS)
Cellectis (CLLS) Upgraded to Buy: Here's Why
After Plunging -27.95% in 4 Weeks, Here's Why the Trend Might Reverse for Cellectis (CLLS)
Other News for CLLS
Cibus Announces Pricing of Public Offering of Class A Common Stock
Cibus, Inc. Announces Proposed Public Offering of Class A Common Stock
Cibus announces proposed public offering of Class A common stock
Cibus Completes First Field Trials in UK for Pod Shatter Reduction in Winter Oilseed Rape
Cellectis Presents Pre-Clinical Evidence of MUC1 CAR T-cells Reducing Triple-Negative Breast Cancer While Preserving Safety